DDInter222 DDInter1592
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Bortezomib {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Rifapentine
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifapentine
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Bortezomib {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Rifabutin
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Bortezomib may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin (Compound) resembles Rifapentine (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)
Bortezomib (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Rifapentine (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) resembles Rifapentine (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Bortezomib (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)